Skye Bioscience
SKYE
58 hedge funds and large institutions have $85.3M invested in Skye Bioscience in 2025 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 29 closing their positions.
117% more capital invested
Capital invested by funds: $39.3M → $85.3M (+$46M)
111% more call options, than puts
Call options by funds: $388K | Put options by funds: $184K
13.87% less ownership
Funds ownership: 79.73% → 65.86% (-14%)
19% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 16
23% less funds holding
Funds holding: 75 → 58 (-17)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
55% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$974K |
| 2 |
FAM
Fred Alger Management
New York
|
+$417K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$216K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$108K |
| 5 |
Two Sigma Investments
New York
|
+$96.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.94M |
| 2 |
BlackRock
New York
|
-$1.63M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$1.31M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.07M |
| 5 |
State Street
Boston,
Massachusetts
|
-$628K |
SKYE Hedge Fund Activity: Q2 2025 in Review
58 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Skye Bioscience (SKYE) for Q2 2025, worth a combined $85.3M — up 117% from $39.3M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of SKYE and 13 opened new positions — a net loss of 16 holders — while 16 trimmed existing stakes and 13 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $974K. The largest seller was Sphera Funds Management, cutting an estimated $1.94M.
- 58 institutional investors held Skye Bioscience (SKYE) as of Q2 2025, down from 75 in Q1 2025.
- Funds reported $85.3M of Skye Bioscience stock for Q2 2025, up 117% quarter-over-quarter.
- 13 funds opened new Skye Bioscience positions in Q2 2025 and 29 closed out, a net change of -16 holders.
- The largest Skye Bioscience buyer in Q2 2025 was Millennium Management, an estimated $974K added.
- The largest Skye Bioscience seller in Q2 2025 was Sphera Funds Management, an estimated $1.94M sold.
Based on aggregated 13F filings for Q2 2025.